|
 |
|
Peter J.E. Verdegem, Ph.D., MBA
|
|
|
Dr. Peter J.E. Verdegem, Unicity’s Chief Science Officer, obtained a MSc in Organic Chemistry from the University of Leiden in the Netherlands. In his specialization he studied the chemistry of the photosynthetic reaction center of plants. After his MSc degree, he started a Ph.D. research project studying the human eye. For this various vitamin A analogues were synthesized and incorporated into rhodopsin, the visual receptor in the retina. NMR allowed to measure internuclear distances in the receptor vitamin A ligand, and thereby a three-dimensional model for the ligand could be constructed. This has resulted in a greater understanding of the fascinating physics that happens in the visual process. In 1998 he was awarded a Ph.D. in Bio-Organic Photochemistry.
He pursued his academic career with post-doctoral research at Stockholm University in Sweden where he developed techniques to study proteins at molecular levels. During a position at Nijmegen University Medical Center in the Netherlands, he studied and developed non-invasive technology to diagnose prostate cancer. After these academic positions he joined Royal Numico Research and Development to develop, and clinically substantiate dietary supplements for a broad variety of health conditions (such as menopause, prostate health, eye health, Alzheimer, ADHD, dyslexia, diabetes, and obesity). Dr. Verdegem’s scientific work has been published in over 30 peer-reviewed publications. In 2004, he moved to Utah, and joined Unicity International to head to Research & Development Department, where he is responsible for product development, clinical substantiation and scientific training of our Business Associates. In 2006 he finished his MBA from the Marriott School of Business at Brigham Young University. |
| |
|
|
|
|
